The evidence regarding this claim is scarce
Around 12 percent of adults in the US have turned to glucagon-like peptide 1 (GLP-1) drugs, according to a 2024 medical survey, which is meant to treat people with Type 2 diabetes
BPC157 / TB500 This combination pairs the gut-healing and tissue-repair properties of BPC157 with the anti-inflammatory, recovery-boosting effects of TB500
Vitamin A It has a role in maintaining normal vision, skin, bones and muscles
doi:10.1016/j.cmet.2010.04.001 5 Verdin E, Ott M
The monoclonal anti-synuclein antibody exidavnemab is currently investigated in a phase 2a trial (NCT06671938, see Table 6) Active Immunotherapy Active immunization strategies are designed to provoke an immune response against oligomeric or insoluble forms of -synuclein